Polymer-based paclitaxel-eluting stents can rarely trigger severe anaphylactic reactions during deployment, necessitating prompt recognition and aggressive resuscitation.
Prompts vigilance for anaphylaxis during paclitaxel-eluting stent deployment; case reports leave incidence and mechanisms open.
We report a patient who experienced an anaphylactic reaction during coronary artery stenting. Immediately after a polymer-based paclitaxel-eluting stent (Taxus, Boston-Scientific) is deployed, the patient developed profound hypotension and an erythematous rash. The case complicated with coronary spasm and a new thrombus formation making a second stent implantation necessary. The reaction was successfully reversed with epinephrine, steroid, antihistaminic, a 9-hr infusion of dopamine, and intraaortic balloon counterpulsation.
No takes yet. Share an insight, caveat, or question.
Türkoğlu et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: